Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MODUL biomarker-driven maintenance treatment trial in first-line metastatic colorectal cancer
NL-OMON45025Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab, capecitabine, fluorouracil, folinic acid, oxaliplatin and 4 more in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (4 arms), sponsored by Roche. Primary endpoints: Early efficacy and Progression-free survival. Started Jun 2015; status: active, not recruiting.
02
Drugs
bevacizumabcapecitabinefluorouracilfolinic acidoxaliplatin
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on NL-OMON45025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45025.